At present, it is assumed that after ligand activation, PPARγ inhibits the proliferation and growth of tumor cells in a dose-dependent manner, which is also associated with the differentiation level of tumor cells, suggesting that PPARγ may be an early diagnostic factor for esophageal cancer, which provides clinicians with a new interventive target for esophageal cancer. Here, PPARG is linked to neoplasm.